Nemaura Pharma has entered into a license agreement with a Global Pharma Company to develop three new Transdermal Patch products. These patches address a multi-Billion dollar market and the agreement reflects the confidence placed in Nemaura’s ability to deliver complex dosage formulations. Previously Nemaura developed a daily transdermal patch for a CNS indication and ANDA subsequently submitted to the FDA.
Nemaura Pharma is a UK based specialist Biotech Company with over 20 products in development, including several complex injectables, using proprietary and differentiated delivery platforms. The company is head-quartered in the University town of Loughborough, and has several development laboratories as well as a GMP clean room suite and IMP license for the manufacture and supply of transdermal, topical, and aseptically manufactured injectable products using gassed isolation technology.